Search Results

The corporate investor arms of Eli Lilly, Sanofi and Pfizer have participated in billions worth of venture capital rounds, but GV is the industry’s biggest spender.

Analysts tentatively welcomed Novo’s new corporate rebrand—so long as it comes with a larger change to the company’s overall business strategy.

Sartorius and Repligen Corporation (NASDAQ:RGEN) today announced the launch of an integrated bioreactor system that incorporates Repligen XCell ® ATF upstream intensification technology into Sartorius’ Biostat STR® bioreactor, simplifying intensified seed train and N perfusion implementation for biopharmaceutical manufacturers.

The life science group Sartorius opened its new Center of Excellence for bioanalytics in Ann Arbor, Michigan, two years after breaking ground in the Tech Loop at Research Park.

Event will feature industry leaders, cutting-edge technology in cell line development CAMBRIDGE-March 16, 2023- Sartorius, a leading international partner of life science research and the biopharmaceutical industry, will host the Sartorius Summit:

Corporate Treasury Positioned with Cash and Liquid Equity Holdings to Seed, Incubate and Accelerate New and Existing Operations

Highlights M3DICINES™ 3D-printed medicines platform. One platform for PharmaTher’s proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply. Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform’s entry point, are planned for Q4 2026. Near-term products. First proprietary 503A peptide products are planned for Q4 2026, followed by a ketamine dissolvable tablet for telehealth in Q1 2027. Rare pediatric NDA with voucher potential. Orphan drug and rare pediatric disease designation applications are planned for October 2026, with a pre-IND meeting in Q1 2027 and an NDA submission targeted for Q4 2028. Approval could earn a priority review voucher; recent vouchers have sold for US$100–155 million. Pipeline expansion into underserved markets. PharmaTher is evaluating three underserved markets where small-batch production is an advantage: ultra-rare diseases with no FDA-approved treatment, psychedelic medicines for clinical trials and special access, and discontinued medicines that mass manufacturing no longer serves. National emergency network. Every CraftMake™ placement can become a node that prints medical countermeasures on demand. PharmaTher plans to pursue readiness contracts with U.S. and Canadian agencies. New website and brand. PharmaTher has launched its new corporate website at PharmaTher.com, and PERSONALIZ3D™ is now M3DICINES™ (M3DICINES.com).